Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
12.41
USD
|
+6.16%
|
|
+2.99%
|
+135.93%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
926.9
|
2,244
|
882.6
|
363.9
|
234.9
|
646.8
|
-
|
-
|
Enterprise Value (EV)
1 |
704.4
|
1,957
|
737.7
|
250.4
|
234.9
|
448.1
|
500.6
|
563.9
|
P/E ratio
|
-15.7
x
|
-39.7
x
|
-10.3
x
|
-3.55
x
|
-2.21
x
|
-5.38
x
|
-4.92
x
|
-5.22
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
29.3
x
|
26.8
x
|
52.3
x
|
41
x
|
24.7
x
|
EV / Revenue
|
-
|
-
|
-
|
20.2
x
|
26.8
x
|
36.2
x
|
31.8
x
|
21.5
x
|
EV / EBITDA
|
-20
x
|
-37.5
x
|
-8.67
x
|
-2.44
x
|
-2.09
x
|
-3.36
x
|
-3.82
x
|
-4.03
x
|
EV / FCF
|
-21.5
x
|
-45.2
x
|
-10.8
x
|
-6.99
x
|
-
|
-4.07
x
|
-4.2
x
|
-4.31
x
|
FCF Yield
|
-4.64%
|
-2.21%
|
-9.23%
|
-14.3%
|
-
|
-24.6%
|
-23.8%
|
-23.2%
|
Price to Book
|
2.27
x
|
7.92
x
|
4.05
x
|
1.94
x
|
-
|
3.33
x
|
5.68
x
|
6.51
x
|
Nbr of stocks (in thousands)
|
32,730
|
36,236
|
36,791
|
39,431
|
44,654
|
52,117
|
-
|
-
|
Reference price
2 |
28.32
|
61.93
|
23.99
|
9.230
|
5.260
|
12.41
|
12.41
|
12.41
|
Announcement Date
|
3/23/20
|
3/9/21
|
3/10/22
|
3/6/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
12.4
|
8.78
|
12.37
|
15.76
|
26.19
|
EBITDA
1 |
-35.23
|
-52.16
|
-85.09
|
-102.8
|
-112.3
|
-133.2
|
-130.9
|
-139.8
|
EBIT
1 |
-35.68
|
-53.04
|
-86.06
|
-104.4
|
-114.8
|
-128.9
|
-144.9
|
-157.5
|
Operating Margin
|
-
|
-
|
-
|
-841.24%
|
-1,307.21%
|
-1,042.5%
|
-919.08%
|
-601.35%
|
Earnings before Tax (EBT)
1 |
-32.32
|
-52.24
|
-85.8
|
-101.1
|
-104.7
|
-120
|
-136.9
|
-136.4
|
Net income
1 |
-32.32
|
-52.24
|
-85.8
|
-101.1
|
-104.7
|
-116.3
|
-137.9
|
-144.5
|
Net margin
|
-
|
-
|
-
|
-814.73%
|
-1,192.47%
|
-940.85%
|
-875.01%
|
-551.63%
|
EPS
2 |
-1.800
|
-1.560
|
-2.340
|
-2.600
|
-2.380
|
-2.307
|
-2.522
|
-2.377
|
Free Cash Flow
1 |
-32.69
|
-43.27
|
-68.11
|
-35.83
|
-
|
-110.1
|
-119.2
|
-130.7
|
FCF margin
|
-
|
-
|
-
|
-288.82%
|
-
|
-890.31%
|
-756.23%
|
-499.15%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/20
|
3/9/21
|
3/10/22
|
3/6/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
3
|
3.231
|
2.905
|
3.269
|
5.152
|
-2.481
|
3.308
|
2.802
|
3.214
|
3.357
|
3.429
|
3.429
|
EBITDA
1 |
-22.43
|
-24.29
|
-24.55
|
-24.94
|
-26.76
|
-26.57
|
-24.09
|
-32.65
|
-
|
-28.96
|
-31.5
|
-33
|
-34.25
|
-34.75
|
EBIT
1 |
-22.68
|
-24.53
|
-24.8
|
-25.24
|
-27.15
|
-27.18
|
-24.69
|
-33.26
|
-27.23
|
-29.59
|
-31.27
|
-31.94
|
-33.14
|
-33.8
|
Operating Margin
|
-
|
-
|
-826.5%
|
-781.12%
|
-934.53%
|
-831.29%
|
-479.23%
|
1,340.67%
|
-823.28%
|
-1,055.89%
|
-972.78%
|
-951.4%
|
-966.56%
|
-985.94%
|
Earnings before Tax (EBT)
1 |
-22.6
|
-24.45
|
-24.65
|
-24.65
|
-26.11
|
-25.66
|
-22.54
|
-30.65
|
-24.54
|
-26.96
|
-28.2
|
-28.71
|
-29.87
|
-31.11
|
Net income
1 |
-22.6
|
-24.45
|
-24.65
|
-24.65
|
-26.11
|
-25.66
|
-22.54
|
-30.65
|
-24.54
|
-26.96
|
-27.59
|
-27.94
|
-29.27
|
-30.88
|
Net margin
|
-
|
-
|
-821.63%
|
-762.98%
|
-898.83%
|
-784.8%
|
-437.6%
|
1,235.55%
|
-741.9%
|
-962.1%
|
-858.5%
|
-832.14%
|
-853.84%
|
-900.52%
|
EPS
2 |
-0.6100
|
-0.6600
|
-0.6600
|
-0.6300
|
-0.6600
|
-0.6500
|
-0.5300
|
-0.6900
|
-0.5500
|
-0.6000
|
-0.6099
|
-0.5437
|
-0.5626
|
-0.5888
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
3/10/22
|
5/10/22
|
8/8/22
|
11/14/22
|
3/6/23
|
5/4/23
|
8/7/23
|
11/7/23
|
3/25/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
222
|
287
|
145
|
114
|
-
|
199
|
146
|
82.9
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-32.7
|
-43.3
|
-68.1
|
-35.8
|
-
|
-110
|
-119
|
-131
|
ROE (net income / shareholders' equity)
|
-19.6%
|
-20.5%
|
-34.1%
|
-50.2%
|
-
|
-64.8%
|
-73.9%
|
-108%
|
ROA (Net income/ Total Assets)
|
-19.2%
|
-19.8%
|
-32%
|
-40.8%
|
-
|
-42.6%
|
-61.7%
|
-87.2%
|
Assets
1 |
168.1
|
263.3
|
268.4
|
247.5
|
-
|
273
|
223.5
|
165.8
|
Book Value Per Share
2 |
12.50
|
7.820
|
5.930
|
4.750
|
-
|
3.730
|
2.180
|
1.910
|
Cash Flow per Share
2 |
-
|
-1.260
|
-1.820
|
-0.8200
|
-
|
-1.940
|
-0.9400
|
-1.020
|
Capex
1 |
1.64
|
1.05
|
1.2
|
3.96
|
-
|
2.92
|
2.44
|
4.6
|
Capex / Sales
|
-
|
-
|
-
|
31.94%
|
-
|
23.58%
|
15.5%
|
17.57%
|
Announcement Date
|
3/23/20
|
3/9/21
|
3/10/22
|
3/6/23
|
3/25/24
|
-
|
-
|
-
|
Last Close Price
12.41
USD Average target price
22.29
USD Spread / Average Target +79.58% Consensus |
1st Jan change
|
Capi.
|
---|
| +135.93% | 647M | | +1.51% | 42.75B | | +48.26% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|